RenovoRX (NASDAQ: RNXT) has announced that the first patient has enrolled in PRISM-TAMP, an investigator-initiated trial sponsored by the University of Vermont (UVM) evaluating the approved chemotherapy gemcitabine delivered through its Trans-Arterial Micro Perfusion (TAMP) platform, enabled by RenovoCath, as neoadjuvant treatment before surgery in patients with borderline pancreatic ductal adenocarcinoma (PDAC).
In a statement, Conor O’Neill, MD, assistant professor at the UVM Larner College of Medicine and surgical oncologist at the UVM Medical Center, and principal investigator of PRISM-TAMP, commented, “For patients with borderline PDAC, treatment before surgery can influence both whether surgery is possible and how completely the tumor can be removed. PRISM-TAMP will assess whether delivering chemotherapy directly near the tumor through TAMP before surgery can improve local therapeutic response and surgical outcomes. We are pleased to have enrolled our first patient in this important study.”
Leesa Gentry, Chief Clinical Officer of RenovoRx, remarked, “As TAMP becomes more well known in the marketplace, physicians have asked how TAMP could be used in borderline PDAC and other settings beyond locally advanced pancreatic cancer, which is the focus of our ongoing Phase III clinical trial. Enrolling the first PRISM-TAMP patient marks an important step for our IIT program as it moves from concept to clinical execution. These capital-efficient trials enable independent investigators to generate safety and tolerability data of new applications for TAMP, while we remain focused on completing the Phase III TIGeR-PaC trial and reporting topline data in the second half of 2027.”
